Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $0.99 which represents a slight increase of $0.10 or 11.24% from the prior close of $0.89. The stock opened at $0.97 and ...

Analysts at Leerink Partnrs upped their FY2024 EPS estimates for Mirum Pharmaceuticals in a research report issued to clients ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.9 which represents a decrease of $-1.41 or -8.65% from the prior close of $16.31. The stock opened at $16.1 and touched a low of $14.19 ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 21.94% Upside As ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from Outperform to Market Perform. Analyst Price Forecast Suggests 6.67% Upside As of ...